TY - JOUR
T1 - Sequential occurrence of small cell and non-small lung cancer in a male patient
T2 - Is it a transformation?
AU - Wahab, Ahsan
AU - Kesari, Kavitha
AU - Chaudhary, Siddique
AU - Khan, Mahin
AU - Khan, Hafiz
AU - Smith, Susan
AU - Boumber, Yanis
N1 - Funding Information:
Y.B. laboratory has been funded by the Fox Chase Cancer Center and Temple University startup funds, DOD Career Development Award LC140074 and in part by the NCI Core Grant P30 CA006927 (to Fox Chase Cancer Center).
Publisher Copyright:
© 2017 Taylor & Francis Group, LLC.
PY - 2017/12/2
Y1 - 2017/12/2
N2 - Lung cancer is one of the leading causes of cancer-related mortality and is categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). We present a patient with epidermal growth factor receptor (EGFR)-mutant-NSCLC who developed metastatic SCLC after initial therapy with second-generation EGFR-tyrosine kinase inhibitor, afatinib. A 65-year-old male non-smoker was diagnosed with adenocarcinoma of the right lung, stage IVA (M1a). Due to tumor positivity for EGFR-Exon 19 deletion, the patient was started on oral afatinib, which resulted in a partial response. After ten months of treatment, he presented in the office with abdominal pain, distension, weight loss and jaundice. He had diffuse skeletal and hepatic metastases on PET/CT scan with interval progression of his cancer. Although the recurrence of lung adenocarcinoma was suspected, the patient was diagnosed with SCLC on liver biopsy. He received two cycles of chemotherapy and died due to pneumonia and sepsis.
AB - Lung cancer is one of the leading causes of cancer-related mortality and is categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). We present a patient with epidermal growth factor receptor (EGFR)-mutant-NSCLC who developed metastatic SCLC after initial therapy with second-generation EGFR-tyrosine kinase inhibitor, afatinib. A 65-year-old male non-smoker was diagnosed with adenocarcinoma of the right lung, stage IVA (M1a). Due to tumor positivity for EGFR-Exon 19 deletion, the patient was started on oral afatinib, which resulted in a partial response. After ten months of treatment, he presented in the office with abdominal pain, distension, weight loss and jaundice. He had diffuse skeletal and hepatic metastases on PET/CT scan with interval progression of his cancer. Although the recurrence of lung adenocarcinoma was suspected, the patient was diagnosed with SCLC on liver biopsy. He received two cycles of chemotherapy and died due to pneumonia and sepsis.
KW - Adenocarcinoma of Lung
KW - Afatinib
KW - Bronchoalveolar Lavage
KW - EGFR Receptors
KW - Poorly differentiated Adenocarcinoma
KW - Resistance
KW - Small Cell Lung Cancer
KW - Transformation
KW - Tyrosine Kinase Inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85038081682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038081682&partnerID=8YFLogxK
U2 - 10.1080/15384047.2017.1394546
DO - 10.1080/15384047.2017.1394546
M3 - Article
C2 - 29157085
AN - SCOPUS:85038081682
SN - 1538-4047
VL - 18
SP - 940
EP - 943
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 12
ER -
